litlas
Log inCreate account

Anthony Letai

Active 1977–2025

138
Papers
39,817
Citations
85
h-index
138
i10-index

Citations

Citations per year for Anthony Letai1975: 1 citations1978: 2 citations1983: 2 citations1984: 1 citations1985: 2 citations1986: 2 citations1987: 1 citations1988: 1 citations1989: 9 citations1990: 5 citations1991: 4 citations1992: 10 citations1993: 14 citations1994: 22 citations1995: 5 citations1996: 12 citations1997: 9 citations1998: 13 citations1999: 4 citations2000: 6 citations2001: 7 citations2002: 6 citations2003: 49 citations2004: 57 citations2005: 102 citations2006: 174 citations2007: 226 citations2008: 321 citations2009: 236 citations2010: 330 citations2011: 346 citations2012: 369 citations2013: 423 citations2014: 407 citations2015: 449 citations2016: 446 citations2017: 566 citations2018: 545 citations2019: 1,648 citations2020: 1,883 citations2021: 1,955 citations2022: 1,641 citations2023: 1,250 citations2024: 1,835 citations2025: 942 citations2026: 19 citations1976–1977: no citations, so these years are not shown1979–1982: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,309 citing papers, 30.4% of this breakdownChina: 2,265 citing papers, 13% of this breakdownGermany: 989 citing papers, 5.7% of this breakdownUnited Kingdom: 940 citing papers, 5.4% of this breakdownItaly: 684 citing papers, 3.9% of this breakdownFrance: 655 citing papers, 3.7% of this breakdownAustralia: 638 citing papers, 3.7% of this breakdownCanada: 505 citing papers, 2.9% of this breakdownSpain: 420 citing papers, 2.4% of this breakdownJapan: 386 citing papers, 2.2% of this breakdownNetherlands: 359 citing papers, 2.1% of this breakdownSwitzerland: 331 citing papers, 1.9% of this breakdown
0%30.4%Other 22.7%

Institutions

Fields

  • Medicine44.5%
  • Biochemistry, Genetics and Molecular Biology44.4%
  • Immunology and Microbiology4.7%
  • Computer Science1.5%
  • Engineering1.1%
  • Chemistry0.7%
  • Other3.1%

Topics

  • Acute Myeloid Leukemia Research5.4%
  • Cell death mechanisms and regulation4.9%
  • Protein Degradation and Inhibitors2.4%
  • Cancer Genomics and Diagnostics2.4%
  • Ubiquitin and proteasome pathways2.2%
  • Histone Deacetylase Inhibitors Research2.1%
  • Other80.6%

Coauthors

All papers

Open in search
  1. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

    Authors: Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Andrew H. Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux, Elizabeth A. Koller, Violaine Havelange, Brian Leber, Jordi Esteve, Jianxiang Wang, Vlatko Pejša, Roman Hájek, Kimmo Porkka, Árpád Illés, David Lavie, Roberto M. Lemoli, Kazuhito Yamamoto, Sung‐Soo Yoon, Jun‐Ho Jang, Su‐Peng Yeh, Mehmet Turgut, Wan‐Jen Hong, Ying Zhou, Jalaja Potluri, Keith W. Pratz - New England Journal of Medicine 2020 cited by 2,771

  2. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

    Authors: Rumani Singh, Anthony Letai, Kristopher A. Sarosiek - Nature Reviews Molecular Cell Biology 2019 cited by 2,074

  3. The landscape of somatic copy-number alteration across human cancers

    Authors: Rameen Beroukhim, Craig H. Mermel, Dale Porter, Guo Wei, Soumya Raychaudhuri, Jerry Donovan, Jordi Barretina, Jesse S. Boehm, Jennifer Dobson, Mitsuyoshi Urashima, Kevin T. Mc Henry, Reid M. Pinchback, Azra H. Ligon, Yoon‐Jae Cho, Leila Haery, Heidi Greulich, Michael Reich, Wendy Winckler, Michael S. Lawrence, Barbara A. Weir, Kumiko Tanaka, Derek Y. Chiang, Adam J. Bass, Alice Loo, Carter Hoffman, John R. Prensner, Ted Liefeld, Qing Gao, Derek Yecies, Sabina Signoretti, Elizabeth A. Maher, Frederic J. Kaye, Hidefumi Sasaki, Joel E. Tepper, Jonathan A. Fletcher, Josep Tabernero, José Baselga, Ming‐Sound Tsao, Francesca Demichelis, Mark A. Rubin, Pasi A. Jänne, Mark J. Daly, Carmelo Nucera, Ross L. Levine, Benjamin L. Ebert, Stacey Gabriel, Anil K. Rustgi, Cristina R. Antonescu, Marc Ladanyi, Anthony Letai, Levi A. Garraway, Massimo Loda, David G. Beer, Lawrence D. True, Aikou Okamoto, Scott L. Pomeroy, Samuel Singer, Todd R. Golub, Eric S. Lander, Gad Getz, William R. Sellers, Matthew Meyerson - Nature 2010 cited by 4,185

  4. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

    Authors: Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat, Brian A. Jonas, Martha Arellano, Pamela S. Becker, Olga Frankfurt, Marina Konopleva, Andrew H. Wei, Hagop M. Kantarjian, Tu Xu, Wan‐Jen Hong, Brenda Chyla, Jalaja Potluri, Daniel A. Pollyea, Anthony Letai - Blood 2018 cited by 1,852

  5. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

    Authors: Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri, Brenda Chyla, Leah J. Hogdal, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L. Ricker, William Blum, Courtney D. DiNardo, Tapan M. Kadia, Martin Dunbar, Rachel Kirby, Nancy Falotico, Joel D. Leverson, Rod Humerickhouse, Mack Mabry, Richard M. Stone, Hagop M. Kantarjian, Anthony Letai - Cancer Discovery 2016 cited by 1,056

  6. An inhibitor of Bcl-2 family proteins induces regression of solid tumours

    Authors: Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker, Robert C. Armstrong, David J. Augeri, Barbara Belli, Milan Bruncko, Thomas L. Deckwerth, Jürgen Dinges, Philip J. Hajduk, Mary K. Joseph, Shinichi Kitada, Stanley J. Korsmeyer, Aaron Kunzer, Anthony Letai, Chi Li, Michael J. Mitten, David G. Nettesheim, Shi-Chung Ng, Paul Nimmer, Jacqueline M. O’Connor, Anatol Oleksijew, Andrew M. Petros, John C. Reed, Shen Wang, Stephen K. Tahir, Craig B. Thompson, Kevin J. Tomaselli, Baole Wang, Michael Wendt, Haichao Zhang, Stephen W. Fesik, Saul H. Rosenberg - Nature 2005 cited by 3,410

  7. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis

    Authors: Rongqing Pan, Jeremy Ryan, Deng Pan, Kai W. Wucherpfennig, Anthony Letai - Cell 2022 cited by 196

  8. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

    Authors: Romain Guièze, Vivian M. Liu, Daniel Rosebrock, Alexis A. Jourdain, María Hernández‐Sánchez, Aina Zurita Martinez, Jing Sun, Elisa ten Hacken, Kaitlyn Baranowski, Philip A. Thompson, Jin-Mi Heo, Zachary Cartun, Ozan Aygün, J. Bryan Iorgulescu, Wandi Zhang, Giulia Notarangelo, Dimitri Livitz, Shuqiang Li, Matthew S. Davids, Anat Biran, Stacey M. Fernandes, Jennifer R. Brown, Ana Lako, Zoe Ciantra, Matthew A. Lawlor, Derin B. Keskin, Namrata D. Udeshi, William G. Wierda, Kenneth J. Livak, Anthony Letai, Donna Neuberg, J. Wade Harper, Steven A. Carr, Federica Piccioni, Christopher J. Ott, Ignaty Leshchiner, Cory M. Johannessen, John G. Doench, Vamsi K. Mootha, Gad Getz, Catherine J. Wu - Cancer Cell 2019 cited by 360

  9. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

    Authors: Rongqing Pan, Leah J. Hogdal, Juliana M. Benito, Donna Bucci, Lina Han, Gautam Borthakur, Jörge E. Cortes, Daniel J. DeAngelo, LaKeisha Debose, Hong Mu, Hartmut Döhner, Verena I. Gaidzik, Ilene Galinsky, Leonard S. Golfman, Torsten Haferlach, Karine G. Harutyunyan, Jianhua Hu, Joel D. Leverson, Guido Marcucci, Markus Müschen, Rachel Newman, Eugene Park, Peter P. Ruvolo, Vivian Ruvolo, Jeremy Ryan, Sonja Schindela, Patrick A. Zweidler‐McKay, Richard M. Stone, Hagop M. Kantarjian, Michael Andreeff, Marina Konopleva, Anthony Letai - Cancer Discovery 2013 cited by 735

  10. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

    Authors: Jennifer L. Guerriero, Alaba Sotayo, Holly Ponichtera, Jessica A. Castrillon, Alexandra L. Pourzia, Sara Schad, Shawn F. Johnson, Ruben D. Carrasco, Suzan Lazo, Roderick T. Bronson, Scott Davis, Mercedes Lobera, Michael A. Nolan, Anthony Letai - Nature 2017 cited by 551

  11. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

    Authors: Qi Zhang, Bridget Riley‐Gillis, Lina Han, Yannan Jia, Alessia Lodi, Haijiao Zhang, Saravanan Ganesan, Rongqing Pan, Sergej Konoplev, Shannon Sweeney, Jeremy Ryan, Yulia Jitkova, Kenneth Dunner, Shaun Grosskurth, Priyanka Vijay, Sujana Ghosh, Charles Lu, Wencai Ma, Stephen E. Kurtz, Vivian Ruvolo, Helen Ma, Connie C. Weng, Cassandra L. Ramage, Natalia Baran, Ce Shi, Tianyu Cai, R. Eric Davis, Venkata Lokesh Battula, Yingchang Mi, Jing Wang, Courtney D. DiNardo, Michael Andreeff, Jeffery W. Tyner, Aaron D. Schimmer, Anthony Letai, Rose Ann Padua, Carlos E. Bueso‐Ramos, Stefano Tiziani, Joel D. Leverson, Relja Popovic, Marina Konopleva - Signal Transduction and Targeted Therapy 2022 cited by 181

  12. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

    Authors: Courtney D. DiNardo, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Michael J. Thirman, Martha Arellano, Mark G. Frattini, Hagop M. Kantarjian, Relja Popovic, Brenda Chyla, Tu Xu, Martin Dunbar, Suresh Agarwal, Rod Humerickhouse, Mack Mabry, Jalaja Potluri, Marina Konopleva, Daniel A. Pollyea - The Lancet Oncology 2018 cited by 712

  13. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations

    Authors: Anthony Letai, Patrick Bhola, Alana L. Welm - Cancer Cell 2021 cited by 280

  14. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

    Authors: Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski, Binyam Yilma, Jeremy Ryan, Thelma Mashaka, Leutz Buon, Sophia Adamia, Haoling Zhu, Yanan Kuang, Abhishek R. Mogili, Abner Louissaint, Stephan Bohl, Annette S. Kim, Anita K. Mehta, Sneha Sanghavi, Youzhen Wang, Erick J. Morris, Ensar Halilovic, Cloud P. Paweletz, David M. Weinstock, Jacqueline S. Garcia, Anthony Letai - Cancer Cell 2020 cited by 174

  15. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

    Authors: Michael Certo, Victoria Del Gaizo Moore, Mari Nishino, Guo Wei, Stanley J. Korsmeyer, Scott A. Armstrong, Anthony Letai - Cancer Cell 2006 cited by 1,261

  16. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis

    Authors: David Lagares, Alba Santos, Paula Grasberger, Fei Liu, Clemens K. Probst, Rod A. Rahimi, Norihiko Sakai, Tobias Kuehl, Jeremy Ryan, Patrick Bhola, Joan Montero, Mohit Kapoor, Murray Baron, Xaralabos Varelas, Daniel J. Tschumperlin, Anthony Letai, Andrew M. Tager - Science Translational Medicine 2017 cited by 232

  17. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

    Authors: Anthony Letai, Michael C. Bassik, Loren D. Walensky, Mia D. Sorcinelli, Solly Weiler, Stanley J. Korsmeyer - Cancer Cell 2002 cited by 1,640

  18. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Authors: Tríona Ní Chonghaile, Kristopher A. Sarosiek, Thanh-Trang T. Vo, Jeremy Ryan, Anupama Tammareddi, Victoria Del Gaizo Moore, Jing Deng, Kenneth C. Anderson, Paul G. Richardson, Yu‐Tzu Tai, Constantine S. Mitsiades, Ursula A. Matulonis, Ronny Drapkin, Richard M. Stone, Daniel J. DeAngelo, David J. McConkey, Stephen E. Sallan, Lewis B. Silverman, Michelle S. Hirsch, Daniel R. Carrasco, Anthony Letai - Science 2011 cited by 595

  19. Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

    Authors: Tríona Ní Chonghaile, Justine E. Roderick, Cian Glenfield, Jeremy Ryan, Stephen E. Sallan, Lewis B. Silverman, Mignon L. Loh, Stephen P. Hunger, Brent L. Wood, Daniel J. DeAngelo, Richard M. Stone, Marian H. Harris, Alejandro Gutiérrez, Michelle A. Kelliher, Anthony Letai - Cancer Discovery 2014 cited by 274

  20. Precision medicine for cancer with next-generation functional diagnostics

    Authors: Adam A. Friedman, Anthony Letai, David E. Fisher, Keith T. Flaherty - Nature reviews. Cancer 2015 cited by 587

  21. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

    Authors: Mary Ann Anderson, Jing Deng, John F. Seymour, Constantine S. Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R. Brown, David Westerman, Éric Ghigo, Ian J. Majewski, David Segal, Sari L. Heitner Enschede, David C.S. Huang, Matthew S. Davids, Anthony Letai, Andrew W. Roberts - Blood 2016 cited by 329

  22. Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment

    Authors: Catherine Gutierrez, Aziz Al’Khafaji, Eric Brenner, Kaitlyn E. Johnson, Satyen H. Gohil, Ziao Lin, Binyamin A. Knisbacher, R. Durrett, Shuqiang Li, Salma Parvin, Anat Biran, Wandi Zhang, Laura Z. Rassenti, Thomas J. Kipps, Kenneth J. Livak, Donna Neuberg, Anthony Letai, Gad Getz, Catherine J. Wu, Amy Brock - Nature Cancer 2021 cited by 111

  23. PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells

    Authors: Josephine Kahn, Peter G. Miller, Alexander J. Silver, Rob S. Sellar, Shruti Bhatt, Christopher J. Gibson, Marie McConkey, Dylan Adams, Brenton G. Mar, Philipp Mertins, Shaunt Fereshetian, Karsten Krug, Haoling Zhu, Anthony Letai, Steven A. Carr, John G. Doench, Siddhartha Jaiswal, Benjamin L. Ebert - Blood 2018 cited by 219

  24. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

    Authors: Joan Montero, Kristopher A. Sarosiek, Joseph D. DeAngelo, Ophélia Maertens, Jeremy Ryan, Dalia Ercan, Huiying Piao, Neil S. Horowitz, Ross S. Berkowitz, Ursula A. Matulonis, Pasi A. Jänne, Philip C. Amrein, Karen Cichowski, Ronny Drapkin, Anthony Letai - Cell 2015 cited by 377